MAGEA3 and cancer: In fact, fusion proteins or peptides derived from some of the first identified CT antigens such as MAGE-A3 and NY-ESO-1 are subject of present clinical phase II and III studies to evaluate their potential as cancer vaccines, e.g. for the treatment of myeloma[6-9].